OrbiMed

  • Harbour BioMed closes Series C financing round

    On July 10, Harbour BioMed announced completion of its Series C financing round of 102.8 million US dollars to accelerate the development of its innovative biopharmaceutical product pipeline targeting cancer, immunologic diseases, and COVID-19.

  • New Horizon Health closes USD30m Series E round

    New Horizon Health, China’s first biotech company to focus on early-stage cancer screening, today announced the completion of a 30 million US dollars Series E financing round, led by Rock Springs Capital, with participation from OrbiMed, Rock Springs Capital, Cormorant Asset Management, CR-CP Life Science Fund, Octagon Capital and existing investor Qiming Venture Partners.

  • MabPlex International closes RMB500m Series B financing round

    This round of financing was led by DT Capital and Golden China Fund, with participation from investment institutions including Sunshine Insurance Group, OrbiMed, China Merchants Securities Investment, Finnova Capital, Horus Capital, Unifortune, and Series A investors GF Venture Capital, Yantai Finance Investment Group and others.